drugset / Trial / NCT00003662

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

NCT00003662

Treatment

Summary

RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating patients who have hematologic cancer or other hematologic or metabolic diseases.

Timeline

Start
1998-08
Primary completion
2001-01
Completion
2001-01

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic Intravenous
Background Busulfan Small molecule Oral
Background Cyclophosphamide Other / unclassified Intravenous
Background Cyclosporine Peptide
Background Melphalan Small molecule
Background Methylprednisolone Other / unclassified Intravenous